P. Clayden

发表

tag 2010 pipeline r eport HiV, tuberculo SiS, and Viral HepatitiS:

S. Collins, S. Jeffery, P. Clayden, 2010 .

Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality?

S. Lawn, T. Cohen, M. Mendelson, 2010, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

C. Giaquinto, N. Klein, D. Gibb, 2015, HIV medicine.

Enhanced and timely investigation of ARVs for use in pregnant women.

N. Ford, L. Mofenson, S. Khoo, 2020, Journal of acquired immune deficiency syndromes.

Why it’s time to say goodbye to stavudine ... everywhere

S. Collins, E. Goemaere, P. Clayden, 2012 .

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

G. Maartens, A. Vos, M. Moorhouse, 2020, The lancet. HIV.

Clinical and population‐based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy

B. Chi, J. Stringer, L. Myer, 2022, Journal of the International AIDS Society.

TAC COMMENTARY ON THE DRAFT 2008 DEPARTMENT OF HEALTH MANAGEMENT OF HIV GUIDELINES 1 -- PRESENTED TO THE SANAC TTT

S. Collins, Krista L. Dong, P. Clayden, 2008 .

Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action

Jennifer M. Zech, S. Lockman, A. Calmy, 2022, Journal of the International AIDS Society.

Weight gain stopping/switch rules for antiretroviral clinical trials.

M. Siedner, E. Delaporte, S. Khoo, 2021, AIDS.

Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.

L. Mofenson, A. Hill, A. Pozniak, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.

M. Siedner, E. Delaporte, S. Khoo, 2022, AIDS.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Preferred antiretroviral drugs for the next decade of scale up

N. Ford, C. Katlama, P. Cahn, 2012, Journal of the International AIDS Society.

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities

C. Flexner, S. Lockman, K. Mayer, 2019, The lancet. HIV.

Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

H. Rees, S. Khoo, S. Lockman, 2019, Journal of the International AIDS Society.

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects

N. Ford, A. Phillips, L. Mofenson, 2019, Journal of the International AIDS Society.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

A. Wensing, D. Kuritzkes, D. Pillay, 2018, The lancet. HIV.

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

N. Ford, C. Flexner, A. Hill, 2018, AIDS.

What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies.

C. Giaquinto, L. Mofenson, T. Puthanakit, 2022, The lancet. HIV.

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review

A. Hill, C. Thorne, P. Clayden, 2018, Journal of virus eradication.

Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding

E. Abrams, A. Slogrove, P. Clayden, 2017, Current opinion in HIV and AIDS.

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank

N. Ford, A. Hill, A. Pozniak, 2017, Current opinion in HIV and AIDS.

The Virus, Vitamins & Vegetables : The South African HIV / AIDS Mystery, Kerry Cullinan and Anso Thorn (Eds.) : book review

P. Clayden, 2009 .

British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008

D. Hawkins, J. Anderson, G. Foster, 2008, HIV medicine.

British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)

Y. Gilleece, A. de Ruiter, H. Lyall, 2014, HIV medicine.

British HIV Association guidelines for the management of HIV infection in pregnant women 2012

Y. Gilleece, A. de Ruiter, H. Lyall, 2012 .

Guidelines for the management of HIV infection in pregnant women 2012

Y. Gilleece, A. de Ruiter, H. Lyall, 2012 .

Guidelines for the management of HIV infection in pregnant women and the prevention of mother‐to‐child transmission of HIV

D. Hawkins, M. Newell, A. de Ruiter, 2005, HIV medicine.

Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV

D. Shingadia, E. Chiappini, E. Nastouli, 2016, HIV medicine.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Cutting the cost of South African antiretroviral therapy using newer, safer drugs.

M. Moorhouse, M. Boffito, W. Venter, 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks

P. Clayden, 2012 .

British HIV Association and Children's HIV Association position statement on infant feeding in the UK 2011

J. Anderson, M. Newell, B. Gazzard, 2011, HIV medicine.

2013 pipeline report: HIV hepatitis C virus (HCV) and tuberculosis (TB) drugs diagnostics vaccines preventive technologies research toward a cure and immune-based and gene therapies in development.

S. Collins, R. Jefferys, P. Clayden, 2013 .

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Starting infants on antiretroviral therapy : clinical : paediatrics

P. Clayden, 2008 .

The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen

P. Clayden, C. Serenata, W. D. Venter, 2017, Current opinion in HIV and AIDS.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.

A. Vos, M. Moorhouse, A. Hill, 2019, The New England journal of medicine.

What we have learned from antiretroviral treatment optimization efforts over the last 5 years?

A. Hill, M. Penazzato, M. Doherty, 2021, AIDS.

International Workshop on HIV and Women 10 – 11 January 2011 , Washington Introduction : what took so long ?

P. Clayden, 2011 .

Safety of Antiretrovirals in Pregnancy

P. Clayden, 2009 .

High rates of HIV acquisition in pregnancy and post partum in Francistown , Botswana

P. Clayden, 2009 .

Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic

M. Moorhouse, A. Hill, W. Venter, 2020, Journal of virus eradication.

Why a universal antiretroviral regimen?

C. Flexner, P. Clayden, W. D. Venter, 2017, Current opinion in HIV and AIDS.

The loss of friends and colleagues from flight MH 17

P. Clayden, 2014 .

What Clinicians Need to Know About the Development of Long-Acting Formulations.

C. Flexner, S. Swindells, David L. Thomas, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of long-acting therapies on the global HIV epidemic.

C. Flexner, S. Rannard, A. Owen, 2021, AIDS.

5.0 Use of antiretroviral therapy in pregnancy

Y. Gilleece, H. Lyall, P. Hay, 2012, HIV medicine.